



Intra-Cellular Therapies Inc.
Investor Relations Department
430 East 29th Street
Suite 900
New York, NY 10016
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: ITCI

Last Trade:	19.29
Trade Time:	4:00 PM ET Sep 22, 2017
Change:	0.04 (+0.208%)
Day Range	18.95 - 19.47
52-Week Range	7.85 - 42.40
Volume	569,858

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Intra-Cellular Therapies is a biopharmaceutical company focused on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder and other neuropsychiatric and neurological disorders.

ITI-007 is in Phase 3 clinical trials as a first-in-class t...
[\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Sep 18, 2017
[Intra-Cellular Therapies to Participate at Upcoming Investor Conferences](#)

Sep 7, 2017
[Intra-Cellular Therapies Announces Positive Topline Data From 6-Week Open-label Safety Switching Study with Lumateperone in Patients with Schizophrenia](#)

Aug 23, 2017
[Intra-Cellular Therapies Announces Positive Regulatory Update On Schizophrenia Program](#)

Aug 9, 2017
[Intra-Cellular Therapies Reports Second Quarter 2017 Financial Results and Provides Corporate Update](#)

Jul 20, 2017
[Intra-Cellular Therapies Presents at the 2017 International College of Neuro-Psychopharmacology \(CINP\) Thematic Meeting on Treatment-Resistant Depression](#)

Upcoming Events [\[View all \]](#)

Sep 25, 2017 1:15 PM ET
[Cantor Fitzgerald Global Healthcare Conference](#)

Sep 26, 2017 11:00 AM ET
[Ladenburg Thalmann 2017 Healthcare Conference](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Mar 1, 2017
[Annual Report \(10-K\)](#)

May 1, 2017
[Proxy Statement \(DEF 14A\)](#)

Aug 9, 2017
[Quarterly Report \(10-Q\)](#)

May 10, 2017
[Quarterly Report \(10-Q\)](#)

Nov 9, 2016
[Quarterly Report \(10-Q\)](#)